Servier: patent settlements were not by-object restrictions
A lawyer for pharmaceutical company Servier said the EU’s antitrust watchdog incorrectly found that agreements delaying the entry of generic rivals to its cardiovascular drug perindopril were by-object restrictions.
To read more
Subscribe to Global Competition Review
Subscribe to unlock unlimited access
Get news, unique commentary, expert analysis and essential resources from the Global Competition Review experts.
Subscribe now